Panel 6 : Vaccines

Objective. To review the literature on progress regarding (1) effectiveness of vaccines for prevention of otitis media (OM) and (2) development of vaccine antigens for OM bacterial and viral pathogens. Data Sources. PubMed database of the National Library of Science. Review Methods. We performed literature searches in PubMed for OM pathogens and candidate vaccine antigens, and we restricted the searches to articles in English that were published between July 2011 and June 2015. Panel members reviewed literature in their area of expertise. Conclusions. Pneumococcal conjugate vaccines (PCVs) are somewhat effective for the prevention of pneumococcal OM, recurrent OM, OM visits, and tympanostomy tube insertions. Widespread use of PCVs has been associated with shifts in pneumococcal serotypes and bacterial pathogens associated with OM, diminishing PCV effectiveness against AOM. The 10-valent pneumococcal vaccine containing Haemophilus influenzae protein D (PHiD-CV) is effective for pneumococcal OM, but results from studies describing the potential impact on OM due to H influenzae have been inconsistent. Progress in vaccine development for H influenzae, Moraxella catarrhalis, and OM-associated respiratory viruses has been limited. Additional research is needed to extend vaccine protection to additional pneumococcal serotypes and other otopathogens. There are likely to be licensure challenges for protein-based vaccines, and data on correlates of protection for OM vaccine antigens are urgently needed. Implications for Practice. OM continues to be a significant health care burden globally. Prevention is preferable to treatment, and vaccine development remains an important goal. As a polymicrobial disease, OM poses significant but not insurmountable challenges for vaccine development.Peer reviewe

Panel 7: otitis media:treatment and complications

Objective: We aimed to summarize key articles published between 2011 and 2015 on the treatment of (recurrent) acute otitis media, otitis media with effusion, tympanostomy tube otorrhea, chronic suppurative otitis media and complications of otitis media, and their implications for clinical practice. Data Sources: PubMed, Ovid Medline, the Cochrane Library, and Clinical Evidence (BMJ Publishing). Review Methods: All types of articles related to otitis media treatment and complications between June 2011 and March 2015 were identified. A total of 1122 potential related articles were reviewed by the panel members; 118 relevant articles were ultimately included in this summary. Conclusions: Recent literature and guidelines emphasize accurate diagnosis of acute otitis media and optimal management of ear pain. Watchful waiting is optional in mild to moderate acute otitis media; antibiotics do shorten symptoms and duration of middle ear effusion. The additive benefit of adenoidectomy to tympanostomy tubes in recurrent acute otitis media and otitis media with effusion is controversial and age dependent. Topical antibiotic is the treatment of choice in acute tube otorrhea. Symptomatic hearing loss due to persistent otitis media with effusion is best treated with tympanostomy tubes. Novel molecular and biomaterial treatments as adjuvants to surgical closure of eardrum perforations seem promising. There is insufficient evidence to support the use of complementary and alternative treatments. Implications for Practice: Emphasis on accurate diagnosis of otitis media, in its various forms, is important to reduce overdiagnosis, overtreatment, and antibiotic resistance. Children at risk for otitis media and its complications deserve special attention

DETECTION OF AUSTRALIA ANTIGEN BY BIOLOGICAL ASSAY IN 'Au NEGATIVE' KIDNEY HOMOGRAFT RECIPIENTS WITH HEPATIC DYSFUNCTION DETECTION OF AUSTRALIA ANTIGEN BY BIOLOGICAL ASSAY IN 'Au NEGATIVE' KIDNEY HOMOGRAFT RECIPIENTS WITH HEPATIC DYSFUNCTION

SUMMARY Rabbits were immunized with the sera from patients with known Au antigenaemia; from kidney homograft recipients who were Au negative with direct conventional tests but who had hepatic dysfunction; and from normal volunteers. Heterologous anti-Au antibodies were raised by the first of these kinds of sera but not by the third. Sera from seven ofthe eleven immunosuppressed kidney recipients of the second group did not raise anti-Au antibodies in the rabbit, but sera from the other four did. The results indicate that the Au antigen may be present in trace quantities in significant numbers of immunosuppressed patients previously thought to be Au negative. However, they do not unequivocally establish an aetiologic association between Au antigenaemia and 'post-transplantation liver disease', probably because of the obscuring and important factor of hepatotoxicity of the immunosuppressive agents

Immunosuppression with cyclophosphamide in the dog.

Cyclophosphamide significantly diminished the canine humoral antibody response to sheep red blood cells and tended to prevent arterial lesions in renal homografts. However, cyclophosphamide failed to prolong renal homograft survival when administered to dogs as the sole immunosuppressive agent, and it did not add to the effectiveness of azathioprine when given as a supplement to the azathioprine and administered simultaneously or sequentially

A Decade Followup in Early Cases of Renal Homotransplantation

Sixty-four consecutive patients underwent renal homotransplantation 10 1/6 to 11½ years ago, 46 from related and 18 from nonrelated living donors. Thirty-six of these recipients were alive when this series was presented to the American Surgical Assocation in 1965. Now, nine years later, 26 (72%) of the 36 still survive, in 22 instances with function of their original grafts. The 10 who died in the interim tended to have subnormal renal function or graft failure. However, the actual causes of death included 2 or more examples each of myocardial infarction, hepatitis, or other systemic infections. The prognosis for achieving a one decade survival was not obviously related to HL-A tissue match. The best results were with related kidneys, within which subgroup 24 (52%) of the original recipients are still alive. However, there was no particular category of consanguineous donor that had a marked superiority. Only 2 of 18 nonrelated recipients are still alive. All 36 patients who were alive in 1965 had a biopsy of their renal homograft. Kidneys that were destined to function for a decade tended to have relatively minor histopathologic abnormalities. If serious glomerular lesions were found, the outlook for long graft survival was grave. Vascular lesions had a somewhat less serious import. Mononuclear cell infiltration, tubular atrophy, and interstitial fibrosis proved prognostically to be the least significant. Long-term followup of these early cases has shown the durability of chronic renal homografts, particularly if these are from related donors, and has demonstrated the very high degree of rehabilitation that could be achieved even in the early days of renal homotransplantation

Detection of Australia antigen by biological assay in `Au negative' kidney homograft recipients with hepatic dysfunction

Rabbits were immunized with the sera from patients with known Au antigenaemia; from kidney homograft recipients who were Au negative with direct conventional tests but who had hepatic dysfunction; and from normal volunteers. Heterologous anti-Au antibodies were raised by the first of these kinds of sera but not by the third. Sera from seven of the eleven immunosuppressed kidney recipients of the second group did not raise anti-Au antibodies in the rabbit, but sera from the other four did. The results indicate that the Au antigen may be present in trace quantities in significant numbers of immunosuppressed patients previously thought to be Au negative. However, they do not unequivocally establish an aetiologic association between Au antigenaemia and `post-transplantation liver disease', probably because of the obscuring and important factor of hepatotoxicity of the immunosuppressive agents